Literature DB >> 17987346

N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.

Carlo Riccardo Rossi1, Simone Mocellin, Sandro Pasquali, Pierluigi Pilati, Donato Nitti.   

Abstract

BACKGROUND: In this study, we tested the hypothesis that the ratio between metastatic and excised lymph nodes ("N-ratio") might have an independent prognostic value in patients with TNM stage-III cutaneous melanoma.
METHODS: The clinical records of 213 melanoma patients who had undergone radical lymph node dissection (RLND) and were found to harbor pathology-proven metastatic disease were used for analysis. The following clinico-pathological variables were considered for the prognostic study: patient's age and sex, primary tumor site, tumor thickness, Clark's level, ulceration, absolute number of positive lymph nodes, total number of excised lymph nodes, TNM stage (IIIA, IIIB, IIIC), and N-ratio (N-ratio A, </=10%; N-ratio B, 10-25%; N-ratio C, >25%).
RESULTS: Patients were categorized into three N-ratio classes according to the percentage of metastatic lymph nodes (N-ratio A, n = 94; N-ratio B, n = 95; N-ratio C, n = 24). The mean follow-up was 40 months. At univariate survival analysis, tumor thickness (P < 0.0001), ulceration (P = 0.046), Clark's level (P = 0.0002), number of positive lymph nodes (P < 0.0001), TNM stage (P < 0.0001), and N-ratio (P < 0.0001) were significantly associated with overall survival (OS). Interestingly, the Cox proportional hazard model showed that, along with tumor thickness (HR 1.069, P = 0.008) and TNM stage (HR 1.696, P = 0.015), N-ratio (HR 1.578, P = 0.012) also independently predicted OS.
CONCLUSIONS: N-ratio is a novel easy-to-obtain independent prognostic factor for melanoma patients with lymph node metastases and might provide clinicians with additional information suitable for patient stratification while choosing adjuvant treatment. Validation of these results in larger prospective series is warranted to implement N-ratio in the routine clinical setting.

Entities:  

Mesh:

Year:  2007        PMID: 17987346     DOI: 10.1245/s10434-007-9641-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Prognostic significance of nodal ratio in cutaneous squamous cell carcinoma of the head and neck.

Authors:  Aviram Mizrachi; Tuvia Hadar; Naomi Rabinovics; Thomas Shpitzer; Dan Guttman; Raphael Feinmesser; Gideon Bachar
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-13       Impact factor: 2.503

2.  Lymph node ratio predicts disease-specific survival in melanoma patients.

Authors:  Yan Xing; Brian D Badgwell; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Anthony Lucci; Janice N Cormier
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

3.  Outcomes of Cutaneous Squamous Cell Carcinoma in the Head and Neck Region With Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis.

Authors:  Axel Sahovaler; Rohin J Krishnan; David H Yeh; Qi Zhou; David Palma; Kevin Fung; John Yoo; Anthony Nichols; S Danielle MacNeil
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-04-01       Impact factor: 6.223

4.  Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?

Authors:  K P Wevers; E Bastiaannet; H P A M Poos; R J van Ginkel; J T Plukker; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

5.  Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.

Authors:  Nicola Mozzillo; Corrado Caracò; Ugo Marone; Gianluca Di Monta; Anna Crispo; Gerardo Botti; Maurizio Montella; Paolo Antonio Ascierto
Journal:  World J Surg Oncol       Date:  2013-02-04       Impact factor: 2.754

6.  Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study.

Authors:  Stefano Uccella; Francesca Falcone; Stefano Greggi; Francesco Fanfani; Pierandrea De Iaco; Giacomo Corrado; Marcello Ceccaroni; Vincenzo Dario Mandato; Stefano Bogliolo; Jvan Casarin; Giorgia Monterossi; Ciro Pinelli; Giorgia Mangili; Gennaro Cormio; Giovanni Roviglione; Alice Bergamini; Anna Pesci; Luigi Frigerio; Silvia Uccella; Enrico Vizza; Giovanni Scambia; Fabio Ghezzi
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.